A Phase Ⅰb Study of Remimazolam Tosylate in Healthy Volunteers

Inclusion Criteria: * Aged ≥18 and ≤55 years. * Weight range 50 to 100 kg and body mass index (BMI) 18 to 26 kg/m2. * Willing and able to comply with the requirements of the protocol. * Provide written informed consent to participate in the study. Exclusion Criteria: * Abnormal results of physical or laboratory examination with clinical significance * With a history of laboratory results that show the presence of hepatitis B surface antigen (HBs Ag), hepatitis C antibody (HCV Ab), or human immunodeficiency virus (HIV). * With evidence of uncontrolled renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction, in the opinion of the investigator or medical monitor. * Subject with clinically significant abnormalities in baseline 12-lead electrocardiogram (ECG) or vital signs（SBP \<90 mmHg or \>140 mmHg，DBP \<50 mmHg or \>90 mmHg；Hr \<50 bpm or \>100 bpm；SpO2 \<95%）. * Has a known sensitivity to benzodiazepines, flumazenil, or anesthetic agents, or a medical condition such that these agents are contraindicated. * Receipt of other medication within 14 days of the first study day. * Blood donation greater than 200 ml or participation in a clinical study of an unlicensed drug in the previous 3 months. * History of smoking or alcohol abuse within 6 months of screening. * History of grapefruit juice or any other foods affect the activity of cytochrome P450 3A4（CYP3A4） within 7 days of screening. * Pregnant,lactating. * Mallampati score ≥3. * Patients who in the opinion of the investigator may not be able to comply with the requirements of the study are not eligible